A new beat Exploring the efficacy and safety of stereotactic arrhythmia radioablation (STAR) for ventricular tachycardia

The failure of anti-arrhythmic drugs and catheter ablation to effectively treat ventricular tachycardia (VT) has prompted exploration of new therapies. Stereotactic Arrhythmia Radioablation (STAR) has emerged as a promising non-invasive option for patients with therapy-refractory VT. STAR uses high-dose radiation to target and ablate pro-arrhythmic regions. This thesis focuses on STAR's knowledge gaps and its potential future role.
In this thesis an overview of preclinical and clinical studies is presented. Preclinical data show that STAR induces dose-dependent electrophysiological changes in targeted areas. Clinical results suggest short-term efficacy and safety for patients with therapy-resistant VT. Results of the first prospective European study on STAR’s effectiveness are presented and demonstrate an 87% reduction in VT episodes, with no observed decline in left ventricular ejection fraction, pulmonary function, or serious treatment-related adverse events. The thesis also explores safety concerns, including implantable cardioverter-defibrillator safety and detailed echocardiographic analyses.
Overall, STAR shows great potential as a treatment for therapy-refractory VT, offering a significant reduction in VT episodes while maintaining a relatively mild short- to mid-term safety profile. This thesis provides a foundation for further research to improve target delineation, long-term efficacy, and safety, and to better understand the mechanisms of this innovative therapy.